7:00 am Morning Check-In: Served with coffee + light breakfast
7:55 am Chair’s Opening Remarks
8:00 am Keynote: Shaping The Future of Skin Therapeutics: Clinical Momentum & Strategic Innovation
Synopsis
- Evaluating progress in dermatological therapies by reviewing approved products and late-stage clinical assets in conditions like acne, atopic dermatitis, and psoriasis
- Exploring market potential in underserved segments of dermatology, including paediatric patients, rare inflammatory diseases, and post-biologic maintenance strategies
- Evaluating tools with the most promise for the future: from AI, synthetic biology platforms, and scalable topical manufacturing to unlock next-gen innovations
Pioneering The Next Generation Of Dermatology Innovation Through Mechanistic Precision, Digital Disruption & Deeper Disease Understanding
8:30 am SCARLETRED AI for Next-Gen Dermatology Research: Blending Human Experience with Machine Learning Precision
Synopsis
- Standardized, high-resolution mobile imaging for consistent and scalable data capture across clinical sites
- Smart Image analysis powered by objective data and machine learning in Psoriasis, Hidradenitis Suppurativa, and other inflammatory skin diseases
- Real-time AI-driven decision support tools to enhance clinical trial design and execution
- Development of digital biomarkers and novel endpoints to accelerate treatment validation in clinical R&D and post-marketing studies
9:00 am Advancing Precision Repigmentation Through Real-World Learnings in Vitiligo
Synopsis
- Key outcomes and safety insights from adult and adolescent trials investigating topical JAK inhibition in vitiligo
- Translating clinical success to pediatric populations and adapting protocols for less extensive disease
- Navigating operational and regulatory challenges including enrollment barriers and long-term data expectations
- Applying lessons from atopic dermatitis programs to improve trial design, endpoint strategy, and FDA alignment in vitiligo
9:30 am Speed Networking
Synopsis
A prime chance to make the most of in-person networking, and forge new connections as new companies enter and existing ones broaden their presence within the dermatology space.
Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.
10:00 am Morning Break & Refreshments
Advancing Precision Dermatology Through Multi-Omic Profiling, Digital Imaging, And Microbiome-Driven Therapies
10:35 am Modulating Microbial Behaviors to Treat Skin Disease: ENS-002 in Atopic Dermatitis & 33 Million Data Points for Targeted Microbial Interventions
Synopsis
- Discover how Concerto’s kChip platform identified ENS‑002 by screening over 5 million microbial combinations
- Highlight the Phase I trial testing ENS‑002’s safety and impact on Staphylococcus aureus in AD patients
- Explore how microbe-based therapies like ENS‑002 can provide long-term relief without the risks of immunosuppression
- Preview the Skin Universe Project’s role in enabling future microbial consortia for other dermatologic conditions
11:05 am Objective Evaluation of Skin Conditions through Standardized Imaging Endpoints
Synopsis
- The challenges and importance of standardized photography
- Standardized imaging endpoints
- Investigator perspective and obtaining patient consent in your study
- AI and the future of dermatology evaluations
11:20 am Achieving Durable Regimentation in Vitiligo Through Novel Targets & New Modalities
Synopsis
- Vitiligo is an autoimmune disease of the skin with significant unmet medical need
- Vitiligo is driven by immune signaling through IFNg, and therapies that target this pathway show promise as effective new treatments
- Relapse occurs in up to 40% of vitiligo patients after stopping therapy and this is due to autoreactive resident memory T cells that can be targeted by blocking IL-15
- Emerging therapeutic options to target identified pathways that drive disease abound, including small molecules, biologics, and RNA interference
11:50 am Lessons Learned: Using AI in Alopecia, Vitiligo and Hidradenitis Suppurativa Clinical Trials
Synopsis
- Two real clinical trial case studies: Alopecia (SALT) and HS (IHS4). Design, operations, outcomes
- Consistent 2D image capture to ensure high-quality inputs
- Key lessons: inter-site variability reduction, real-time image QC to avoid reshoots; app-based, device-agnostic
12:00 pm Lunch & Learn: Hosted by Premier Research
Synopsis
Invitation only session hosted by Premier Research. For all other attendees, lunch is provided in the exhibition area.
Charting The Future Of Dermatology R&D: Emerging Science, Novel Modalities & Translational Breakthroughs In Inflammatory Skin Disease
1:00 pm Targeting the Inflammasome to Treat Chronic Inflammatory Skin Diseases: Clinical & Preclinical Advances in Atopic Dermatitis & Alopecia Areata
Synopsis
- Presenting Phase 2 clinical trial data demonstrating the efficacy and safety of a novel inflammasome inhibitor targeting GPCR19 in patients with mild-to-moderate Atopic Dermatitis
- Highlighting preclinical results in canine models using oral formulation showing potent suppression of NLRP3 inflammasome activation, supporting the development of 2nd generation compounds
- Sharing early-stage data in alopecia areata showing restoration of hair growth through immune modulation, including inflammasome inhibition and upregulation of regulatory T cells by 2nd generation GPCR19 agonist
- Exploring a dual-acting mechanism that combines inhibition of inflammasome assembly and cytokine signalling as a differentiated strategy for long-term control of chronic skin inflammation such as rosacea and acne
1:30 pm Veradermics Pattern Hairloss Studies: Efficacy Endpoints with Validated Imaging Tools
Synopsis
- Founded by practicing dermatologists, ensuring clinical relevance and patient-centered innovation
- VDPHL: A novel, non-hormonal oral investigational drug targeting androgenetic alopecia (AGA) that could offer a differentiated safety and efficacy profile
- High quality, standardized, reproducible imaging builds confidence for quality oversight and quantitative measurements for regulatory endpoints submission
2:00 pm Scientific Poster Session
Synopsis
This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in dermatology therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.
2:30 pm Afternoon Break & Refreshments
Precision Immunomodulation, Targeted Innovation & Rethinking Route Of Delivery For The Next Generation Of Skin Therapies
3:00 pm Harnessing Immunomodulation to Transform Atopic Dermatitis & Beyond
Synopsis
- Immune mediation may result in complex dermatologic pathologies
- Immunomodulating, specifically focusing on T cells, may positively contribute to disease management
- Targeting the OX40 pathway in dermatology, eg atopic dermatitis, may result in sustained changes, representing remission (with case studies)
- Designing biologics with extended dosing intervals and low immunogenicity to reduce treatment burden and improve adherence
- Translational strategies are able to bridge mechanistic understanding to clinic-ready molecules that balance potency, safety, and patient convenience
3:30 pm Improving Clinical Execution & Translational Rigor to Unlock Success in Atopic Dermatitis and Alopecia Trials
Synopsis
- Key learnings from a 400-patient blinded trial highlight the importance of early patient selection precision and site training quality
- Bridging systemic and local biomarkers through longitudinal sampling to understand dynamic disease resolution beyond static endpoints
- Enhancing trial design by capturing real-time lesion evolution using intensive clinical sampling during active disease
- Strengthening translational frameworks to better connect molecular change with clinically meaningful improvement in dermatologic endpoints
4:00 pm Leveraging Genetically Guided Antibody Strategies to Repair Barrier Dysfunction and Immune Dysregulation in Atopic Dermatitis
Synopsis
- Dual inhibition of kallikrein‑5 and ‑7 offers a protease‑based mechanism that intersects barrier dysfunction, inflammation, and itch in AD
- Unlike standard Th2‑targeted biologics, targeting KLK5/7 represents an orthogonal pathway informed by Netherton syndrome genetics and human expression datasets ex vivo human explant data show rapid improvements in epidermal integrity, reduced keratinocyte proliferation, and restoration of barrier proteins such as desmoglein‑1
- A next‑generation bispecific antibody combining KLK5/7 inhibition with IL‑13 blockade is being advanced to enhance efficacy across barrier and inflammation axes
4:30 pm Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development?
Synopsis
- How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective?
- Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach is most appropriate? How can we best utilize both routes to ensure there is a treatment fit for everyone?
- How are both approaches evolving to better meet patient needs, from systemics tackling severe or widespread disease to topicals aiming for convenience, safety, or even disease modification?
- What are the key trade-offs between topical and systemic treatments in terms of patient adherence, cost, quality of life, and long-term disease control and how can trials be designed to reflect this?